Agenus | AGEN - Operating Profit


Agenus reported $14.4M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -87.15M 13.54M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
J&J USD 5.59B 1.81B Dec/2025
Jiangsu Hengrui CNY 2.25B 848.02M Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
MacroGenics USD -12.1M 30.74M Dec/2025
Merck EUR 474M 738M Dec/2025
Merck USD 6.24B 318M Dec/2025
Northwest Biotherapeutics USD -14.8M 2.66M Sep/2024
Novartis USD 4.06B 437M Dec/2025
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Veracyte USD 24.63M 1.52M Dec/2025